# PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient

> **NCT03295695** · EARLY_PHASE1 · WITHDRAWN · sponsor: **H. Lee Moffitt Cancer Center and Research Institute**

## Conditions studied

- Breast Cancer
- Breast Cancer, Female
- Breast Cancer, Male
- Breast Neoplasms

## Interventions

- **DIAGNOSTIC_TEST:** Fluoro-D-glucose-positron Emission Tomography
- **BIOLOGICAL:** 2-deoxy-2-[18F]fluoro-D-glucose (FDG)
- **DIAGNOSTIC_TEST:** Echocardiogram

## Key facts

- **NCT ID:** NCT03295695
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-12
- **Primary completion:** 2021-12
- **Final completion:** 2022-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** closure of radiolaboratory
- **Last updated:** 2020-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03295695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03295695, "PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03295695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*